Your session is about to expire
← Back to Search
Melphalan/HDS for Intrahepatic Cholangiocarcinoma
Study Summary
This trial will compare two groups of patients with intrahepatic cholangiocarcinoma, one of which will receive high-dose chemotherapy delivered specifically to the liver. The other group will continue with the standard cisplatin and gemcitabine treatment. The results will be measured in terms of overall survival.
- Intrahepatic Cholangiocarcinoma
- Cholangiocarcinoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many individuals are in this control group?
"This study is no longer recruiting participants. The trial's first posting was on 4/10/2018, with the most recent edit on 3/23/2022. There are currently 1112 trials for Melphalan/HDS and 224 for bile duct cancer that are looking for patients."
Can people with the required medical conditions enroll in this study right now?
"Unfortunately, this clinical trial is no longer recruiting patients, as stated on clinicaltrials.gov. The trial was initially posted on April 10th, 2018 but was last updated on March 23rd, 2022. Although this specific study is not looking for participants, there are 1,336 other trials that are."
What other scientific research has been completed on Melphalan/HDS?
"There are 1112 studies currently being conducted on Melphalan/HDS. Of those, 359 are clinical trials in Phase 3. Most of the studies for Melphalan/HDS are based in Shanghai, but there are 53507 locations running studies for this treatment."
What are the most common conditions that Melphalan/HDS is effective in treating?
"Melphalan/HDS is commonly used to treat neoplasm metastasis. It can also be used to treat conditions including urinary bladder, advanced testicular cancer, and small cell lung cancer (sclc)."
Share this study with friends
Copy Link
Messenger